Literature DB >> 21653319

Targeting RAD51 phosphotyrosine-315 to prevent unfaithful recombination repair in BCR-ABL1 leukemia.

Artur Slupianek1, Yashodhara Dasgupta, Shu-Yue Ren, Ewa Gurdek, Milene Donlin, Margaret Nieborowska-Skorska, Fabrice Fleury, Tomasz Skorski.   

Abstract

Chronic myeloid leukemia chronic phase (CML-CP) CD34(+) cells contain numerous DNA double-strand breaks whose unfaithful repair may contribute to chromosomal instability and disease progression to blast phase (CML-BP). These phenomena are often associated with the appearance of imatinib-resistant BCR-ABL1 kinase mutants (eg, T315I) and overexpression of BCR-ABL1. Here we show that BCR-ABL1 (nonmutated and T315I mutant) promoted RAD51 recombinase-mediated unfaithful homeologous recombination repair (HomeoRR) in a dosage-dependent manner. BCR-ABL1 SH3 domain interacts with RAD51 proline-rich regions, resulting in direct phosphorylation of RAD51 on Y315 (pY315). RAD51(pY315) facilitates dissociation from the complex with BCR-ABL1 kinase, migrates to the nucleus, and enhances formation of the nuclear foci indicative of recombination sites. HomeoRR and RAD51 nuclear foci were strongly reduced by RAD51(Y315F) phosphorylation-less mutant. In addition, peptide aptamer mimicking RAD51(pY315) fragment, but not that with Y315F phosphorylation-less substitution, diminished RAD51 foci formation and inhibited HomeoRR in leukemia cells. In conclusion, we postulate that BCR-ABL1 kinase-mediated RAD51(pY315) promotes unfaithful HomeoRR in leukemia cells, which may contribute to accumulation of secondary chromosomal aberrations responsible for CML relapse and progression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21653319      PMCID: PMC3148158          DOI: 10.1182/blood-2010-09-307256

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

Review 1.  Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis.

Authors:  Mary Ellen Moynahan; Maria Jasin
Journal:  Nat Rev Mol Cell Biol       Date:  2010-03       Impact factor: 94.444

2.  Multiple sub-microscopic genomic lesions are a universal feature of chronic myeloid leukaemia at diagnosis.

Authors:  J S Khorashad; V A De Melo; H Fiegler; G Gerrard; D Marin; J F Apperley; J M Goldman; L Foroni; A G Reid
Journal:  Leukemia       Date:  2008-07-31       Impact factor: 11.528

3.  c-ABL tyrosine kinase stabilizes RAD51 chromatin association.

Authors:  Hiroko Shimizu; Milena Popova; Fabrice Fleury; Masahiko Kobayashi; Naoyuki Hayashi; Isao Sakane; Hitoshi Kurumizaka; Ashok R Venkitaraman; Masayuki Takahashi; Ken-ichi Yamamoto
Journal:  Biochem Biophys Res Commun       Date:  2009-03-11       Impact factor: 3.575

4.  Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.

Authors:  Heiko Konig; Mhairi Copland; Su Chu; Richard Jove; Tessa L Holyoake; Ravi Bhatia
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

5.  BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair.

Authors:  Margret S Fernandes; Mamatha M Reddy; Jeffrey R Gonneville; Scott C DeRoo; Klaus Podar; James D Griffin; David M Weinstock; Martin Sattler
Journal:  Blood       Date:  2009-07-01       Impact factor: 22.113

6.  Detection of c-Abl kinase-promoted phosphorylation of Rad51 by specific antibodies reveals that Y54 phosphorylation is dependent on that of Y315.

Authors:  Milena Popova; Hiroko Shimizu; Ken-ichi Yamamoto; Mickael Lebechec; Masayuki Takahashi; Fabrice Fleury
Journal:  FEBS Lett       Date:  2009-05-07       Impact factor: 4.124

7.  BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair.

Authors:  Kimberly Cramer; Margaret Nieborowska-Skorska; Mateusz Koptyra; Artur Slupianek; Emir Tyrone P Penserga; Connie J Eaves; Walter Aulitzky; Tomasz Skorski
Journal:  Cancer Res       Date:  2008-09-01       Impact factor: 12.701

8.  BCR/ABL induces chromosomal instability after genotoxic stress and alters the cell death threshold.

Authors:  J Dierov; P V Sanchez; B A Burke; H Padilla-Nash; M E Putt; T Ried; M Carroll
Journal:  Leukemia       Date:  2008-11-20       Impact factor: 11.528

9.  Cancer induction by restriction of oncogene expression to the stem cell compartment.

Authors:  María Pérez-Caro; César Cobaleda; Inés González-Herrero; Carolina Vicente-Dueñas; Camino Bermejo-Rodríguez; Margarita Sánchez-Beato; Alberto Orfao; Belén Pintado; Teresa Flores; Manuel Sánchez-Martín; Rafael Jiménez; Miguel A Piris; Isidro Sánchez-García
Journal:  EMBO J       Date:  2008-11-27       Impact factor: 11.598

10.  DIDS, a chemical compound that inhibits RAD51-mediated homologous pairing and strand exchange.

Authors:  Takako Ishida; Yoshimasa Takizawa; Takashi Kainuma; Jin Inoue; Tsutomu Mikawa; Takehiko Shibata; Hidekazu Suzuki; Satoshi Tashiro; Hitoshi Kurumizaka
Journal:  Nucleic Acids Res       Date:  2009-03-30       Impact factor: 16.971

View more
  26 in total

1.  Genomic instability in chronic myeloid leukemia: targets for therapy?

Authors:  N Muvarak; P Nagaria; F V Rassool
Journal:  Curr Hematol Malig Rep       Date:  2012-06       Impact factor: 3.952

Review 2.  Genomic instability is a principle pathologic feature of FLT3 ITD kinase activity in acute myeloid leukemia leading to clonal evolution and disease progression.

Authors:  Melanie T Rebechi; Keith W Pratz
Journal:  Leuk Lymphoma       Date:  2017-02-06

Review 3.  Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia.

Authors:  Elias J Jabbour; Timothy P Hughes; Jorge E Cortés; Hagop M Kantarjian; Andreas Hochhaus
Journal:  Leuk Lymphoma       Date:  2013-11-12

4.  Electrophilic fatty acids impair RAD51 function and potentiate the effects of DNA-damaging agents on growth of triple-negative breast cells.

Authors:  Alparslan Asan; John J Skoko; Chen-Shan Chen Woodcock; Bentley M Wingert; Steven R Woodcock; Daniel Normolle; Yi Huang; Jeremy M Stark; Carlos J Camacho; Bruce A Freeman; Carola A Neumann
Journal:  J Biol Chem       Date:  2018-11-26       Impact factor: 5.157

5.  Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases.

Authors:  Yashodhara Dasgupta; Mateusz Koptyra; Grazyna Hoser; Kanchan Kantekure; Darshan Roy; Barbara Gornicka; Margaret Nieborowska-Skorska; Elisabeth Bolton-Gillespie; Sabine Cerny-Reiterer; Markus Müschen; Peter Valent; Mariusz A Wasik; Christine Richardson; Oliver Hantschel; Heiko van der Kuip; Tomasz Stoklosa; Tomasz Skorski
Journal:  Blood       Date:  2016-02-10       Impact factor: 22.113

Review 6.  Ligand-targeted theranostic nanomedicines against cancer.

Authors:  Virginia J Yao; Sara D'Angelo; Kimberly S Butler; Christophe Theron; Tracey L Smith; Serena Marchiò; Juri G Gelovani; Richard L Sidman; Andrey S Dobroff; C Jeffrey Brinker; Andrew R M Bradbury; Wadih Arap; Renata Pasqualini
Journal:  J Control Release       Date:  2016-01-06       Impact factor: 9.776

Review 7.  Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop.

Authors:  Richard A Van Etten; Michael Mauro; Jerald P Radich; John M Goldman; Giuseppe Saglio; Catriona Jamieson; Simona Soverini; Carlo Gambacorti-Passerini; Rüdiger Hehlmann; Giovanni Martinelli; Danilo Perrotti; David T Scadden; Tomasz Skorski; Ayalew Tefferi; Tariq I Mughal
Journal:  Leuk Lymphoma       Date:  2012-12-10

Review 8.  Targeting chronic myeloid leukemia stem cells.

Authors:  Ross Kinstrie; Mhairi Copland
Journal:  Curr Hematol Malig Rep       Date:  2013-03       Impact factor: 3.952

9.  Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile.

Authors:  Kimberly Cramer-Morales; Margaret Nieborowska-Skorska; Kara Scheibner; Michelle Padget; David A Irvine; Tomasz Sliwinski; Kimberly Haas; Jaewoong Lee; Huimin Geng; Darshan Roy; Artur Slupianek; Feyruz V Rassool; Mariusz A Wasik; Wayne Childers; Mhairi Copland; Markus Müschen; Curt I Civin; Tomasz Skorski
Journal:  Blood       Date:  2013-07-08       Impact factor: 22.113

Review 10.  Homologous recombination and its regulation.

Authors:  Lumir Krejci; Veronika Altmannova; Mario Spirek; Xiaolan Zhao
Journal:  Nucleic Acids Res       Date:  2012-03-30       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.